GLP1R and diabetes mellitus: 2014 also welcomed two new once-weekly, long-acting glucagon-like peptide 1 (GLP-1) receptor agonists for type 2 diabetes mellitus – albiglutide and dulaglutide – following the success of once-weekly exenatide.